July 1, 2021
I like to continue to learn from experience as an investor.
TRICIDA SAYS SIGNIFICANTLY REDUCING ITS HEADCOUNT FROM 152 TO 59 PEOPLE
Published: 10/29/2020 12:02 GMT
Tricida Inc (TCDA) - Tricida Provides Update on FDA Interactions.
Tricida Inc - Held End-of-review Conference As a Type a Meeting With Division of Cardiology and Nephrology of U.S. FDA on October 20, 2020.
Tricida Inc - Believes FDA Will Require Evidence of Veverimer's Effect on Ckd Progression From a Near-term Interim Analysis of Valor-ckd Trial.
Tricida Inc - Re-organizing Company to Extend Its Financial Runway in Order to Maximize Options for Bringing Veverimer to Patients.
Tricida Inc - Significantly Reducing Its Headcount From 152 to 59 People.
Tricida Inc - Reduction in Headcount Will Reduce Tricida's Annual Operating Costs by Approximately $25 Million.
Tricida Inc - Continues to Believe That Its Current Development Program for Veverimer is an Appropriate Candidate for Accelerated Approval.
Tricida Inc - Held End-of-review Conference As a Type a Meeting With Division of Cardiology and Nephrology of U.S. FDA on October 20, 2020.
Tricida Inc - Believes FDA Will Require Evidence of Veverimer's Effect on Ckd Progression From a Near-term Interim Analysis of Valor-ckd Trial.
Tricida Inc - Re-organizing Company to Extend Its Financial Runway in Order to Maximize Options for Bringing Veverimer to Patients.
Tricida Inc - Significantly Reducing Its Headcount From 152 to 59 People.
Tricida Inc - Reduction in Headcount Will Reduce Tricida's Annual Operating Costs by Approximately $25 Million.
Tricida Inc - Continues to Believe That Its Current Development Program for Veverimer is an Appropriate Candidate for Accelerated Approval.
No comments:
Post a Comment